Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advinus Therapeutics has entered into a discovery and development partnership with Celgene Global Health (CGH) to focus on therapies for Visceral Leishmaniasis (VL), also known as Kala Azar.
Subscribe to our email newsletter
The aim of the partnership is to identify and develop compounds that are safe and effective against VL parasites.
The collaboration underlines the relative experience and expertise of both companies in analytical chemistry, discovery biology, screening and pre-formulation.
Advinus managing director and CEO Rashmi Barbhaiya said the collaboration utilises a wealth of early discovery research breakthroughs from Celgene and Advinus’ capabilities to translate such breakthroughs into drug candidates with speed and cost-effectiveness.
Celgene Global Health CEO Jerome B Zeldis said they look forward to working with Advinus to derive VL drugs using the vast chemical library of Celgene as a starting point for development.
Advinus is an emerging drug discovery and development company that caters to the pharmaceutical and agrochemical industries.